Manages OA. 1.2 Rheumatoid Arthritis. ANDA 204776, held by Micro Labs. Celecoxib.
As of Nov 15, 2026, ANDA 204776 (Celecoxib), held by Micro Labs, was first approved by FDA on Apr 30, 2018, with 5 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Celecoxib is indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis For the management of the signs and symptoms of OA. 1.2 Rheumatoid Arthritis For the management of the signs and symptoms of RA. 1.3 Juvenile Rheumatoid Arthritis For the management of the signs and symptoms of JRA in patients 2 years and older. 1.4 Ankylosing Spondylitis For the management of the signs and symptoms of AS. 1.5 Acute Pain For the management of acute pain in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2018 | Original application | Approved | None posted |
| Dec 31, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 9, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 6, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 6, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 27, 2018 | Supplement 1Manufacturing | Approved | None posted |
| Apr 30, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters